Some patient-related and tumor-load variables such as age, comorbidities, beta-2-microglobulin levels (B2M), lymphocytosis or lymphocyte doubling time (LDT) are available in virtually all patients and remain valid in predicting TTFT [76,77]. This evidence concerns the gene B2M and neoplasm.